【24h】

Current treatment options for esophageal diseases

机译:食管疾病的当前治疗方案

获取原文

摘要

Exciting new developments-pharmacologic, endoscopic, and surgical-have arisen for the treatment of many esophageal diseases. Refractory gastroesophageal reflux disease presents a therapeutic challenge, and several new options have been proposed to overcome an insufficient effectiveness of proton pump inhibitors. In patients with distal esophageal spasm, drugs and endoscopic treatments are the current mainstays of the therapeutic approach. Treatment with proton pump inhibitors (or antireflux surgery) should be considered in patients with Barrett's esophagus, since a recent meta-analysis demonstrated a 71% reduction in risk of neoplastic progression. Endoscopic resection combined with radiofrequency ablation is the standard of care in patients with early esophageal adenocarcinoma. Mucosal squamous cancer may also be treated endoscopically, preferably with endoscopic submucosal dissection. Patients with upper esophageal cancer often refrain from surgery. Robot-assisted, thoracolaparoscopic, minimally invasive esophagectomy may be an appropriate option for these patients, as the robot facilitates a good overview of the upper mediastinum. Induction chemoradiotherapy is currently considered as standard treatment for patients with advanced squamous cell carcinoma, while the role of neoadjuvant therapy for adenocarcinoma remains controversial. A system for defining and recording perioperative complications associated with esophagectomy has been recently developed and may help to find predictors of mortality and morbidity.
机译:令人兴奋的新发展 - 药物,内窥镜和外科手术,用于治疗许多食管疾病。难治性胃食管反流疾病呈现治疗性挑战,已经提出了几种新选择来克服质子泵抑制剂的不足效力。在远端食管痉挛的患者中,药物和内窥镜治疗是治疗方法的目前的主体。在Barrett食管患者中应考虑用质子泵抑制剂(或抗反射手术)治疗,因为最近的Meta分析表明肿瘤进展的风险降低了71%。内镜切除结合射频消融是早期食管腺癌患者的护理标准。粘膜鳞癌也可以内窥镜癌,优选具有内窥镜粘膜粘膜释放。食管癌癌症的患者经常避免手术。 Robot-assisted, thoracolaparoscopic, minimally invasive esophagectomy may be an appropriate option for these patients, as the robot facilitates a good overview of the upper mediastinum.感应化学疗法目前被认为是针对晚期鳞状细胞癌患者的标准治疗,而Neoadjuvant治疗对腺癌的作用仍存在争议。最近开发了一种用于定义和记录与食道切除术相关的围手术期并发症的系统,并可能有助于寻找死亡率和发病率的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号